Clinical trial · Observational
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes
NCT00327236CI-TRIAL-00038041completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Paraneoplastic Syndromes | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Immunologic responses to tumor antigens in vitro
- timeFrame
- throughout study
- description
- ELISPOT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
Show eligibility criteria text
Inclusion Criteria: * Neurological disease which is suspected to be paraneoplastic * No known active additional malignancy other than non-melanoma skin cancer Exclusion Criteria: * Known central nervous system (CNS) metastasis * Known active additional malignancy * No pulmonary disease which limits daily activities if leukapheresis: must be 14 or older no known hepatitis B or C, HIV, or syphilis (by history or prior negative tests) no known IV drug users HgB \> 8.5 WBC \> 3,500 platelets \> 100,000 INR \< 2 if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known IV drug users HgB \> 10 WBC \> 3,500 platelets \> 100,000 INR \< 2 if lumbar puncture: platelets \> 120,000 INR \< 1.2 must be 14 or older
References
Publications (0)
Data not yet available
No reference posted for this study.